DocumentGILEAD SCIENCES ANNOUNCES THIRD QUARTER 2023 FINANCIAL RESULTS
Product Sales Excluding Veklury Increased 5% Year-Over-Year to $6.4 billion
Biktarvy Sales Increased 12% Year-Over-Year to $3.1 billion
Oncology Sales Increased 33% Year-Over-Year to $769 million
Foster City, CA, November 7, 2023 - Gilead Sciences, Inc. (Nasdaq: GILD) announced today its results of operations for the third quarter of 2023.
“Gilead has now delivered two years of consistent growth in our base business. In the third quarter, this continued growth was driven by both Virology and Oncology,” said Daniel O’Day, Gilead's Chairman and Chief Executive Officer. “Our clinical momentum also remains strong, and highlights this quarter included new data on Trodelvy with pembrolizumab in first-line metastatic non-small cell lung cancer. In Virology, we completed enrollment for Phase 3 trials of lenacapavir for HIV prevention and oral obeldesivir for COVID-19. We are looking forward to advancing these and other potential new options for patients over the coming months.”
Third Quarter 2023 Financial Results
•Total third quarter 2023 revenue of $7.1 billion was flat compared to the same period in 2022, primarily driven by increased sales in Oncology and HIV, offset by lower Veklury® (remdesivir) and chronic hepatitis C virus (“HCV”) product sales.
•Diluted Earnings Per Share (“EPS”) increased to $1.73 for the third quarter of 2023 compared to $1.42 for the same period in 2022, and non-GAAP diluted EPS increased to $2.29 for the third quarter of 2023 compared to $1.90 for the same period in 2022. The increases in GAAP and non-GAAP diluted EPS were primarily driven by lower tax expense, partially offset by net higher total costs and expenses.
•As of September 30, 2023, Gilead had $8.0 billion of cash, cash equivalents and marketable debt securities, up from $7.6 billion as of December 31, 2022.
•During the third quarter of 2023, Gilead generated $1.8 billion in operating cash flow.
•During the third quarter of 2023, Gilead repaid $2.3 billion of debt, paid dividends of $953 million and repurchased $300 million of common stock. Additionally, Gilead issued senior unsecured notes in an aggregate principal amount of $2.0 billion.
Product Sales Performance
Total third quarter 2023 product sales of $7.0 billion was flat compared to the same period in 2022, reflecting continued growth in the base business, offset by lower Veklury sales. Total product sales, excluding Veklury, increased 5% to $6.4 billion in the third quarter of 2023 compared to the same period in 2022, primarily due to increased sales in Oncology and HIV, partially offset by lower HCV sales.
HIV product sales increased 4% to $4.7 billion in the third quarter of 2023 compared to the same period in 2022, primarily driven by higher demand and channel inventory dynamics, partially offset by lower average realized price due to a shift in channel mix.
•Biktarvy® (bictegravir 50mg/emtricitabine 200mg (“FTC”)/tenofovir alafenamide 25mg (“TAF”)) sales increased 12% year-over-year in the third quarter of 2023, primarily driven by higher demand, as well as favorable channel inventory.
•Descovy® (FTC 200mg/TAF 25mg) sales increased 2% year-over-year in the third quarter of 2023, primarily driven by higher demand, partially offset by pricing dynamics in the United States.
The Liver Disease portfolio sales, which includes HCV, chronic hepatitis B virus (“HBV”), and chronic hepatitis delta virus (“HDV”), decreased 10% to $706 million in the third quarter of 2023 compared to the same period in 2022, as higher HCV patient starts were more than offset by unfavorable pricing dynamics, primarily due to the resolution of a rebate claim in HCV in the third quarter of 2022.
Cell Therapy product sales increased 22% to $486 million in the third quarter of 2023 compared to the same period in 2022.
•Yescarta® (axicabtagene ciloleucel) sales increased 23% year-over-year to $391 million in the third quarter of 2023, primarily driven by strong demand in the second- and third-line settings for relapsed or refractory (“R/R”) large B-cell lymphoma (“LBCL”) outside of the United States.
•Tecartus® (brexucabtagene autoleucel) sales increased 18% year-over-year to $96 million in the third quarter of 2023, primarily driven by increased demand in R/R mantle cell lymphoma (“MCL”) and R/R adult acute lymphoblastic leukemia (“ALL”).
Trodelvy® (sacituzumab govitecan-hziy) sales increased 58% to $283 million in the third quarter of 2023 compared to the same period in 2022, primarily driven by higher demand in both the United States and Europe.
Veklury sales decreased 31% to $636 million for the third quarter of 2023 compared to the same period in 2022, primarily driven by lower rates of COVID-19 related hospitalizations in all regions. Veklury sales generally reflect COVID-19 related rates and severity of infections and hospitalizations, as well as the availability, uptake and effectiveness of vaccinations and alternative treatments for COVID-19.
Third Quarter 2023 Product Gross Margin, Operating Expenses and Effective Tax Rate
•Product gross margin was 77.6% for the third quarter of 2023 compared to 80.0% for the same period in 2022, primarily driven by intangible asset amortization expenses related to the pretreated HR+/HER2- metastatic breast cancer indication for Trodelvy following its approval in February 2023, as well as product mix. Non-GAAP product gross margin was 85.9% for the third quarter of 2023 compared to 86.8% in the same period in 2022, primarily driven by product mix.
•Research & development (“R&D”) expenses for the third quarter of 2023 were $1.5 billion compared to $1.1 billion in the same period in 2022. Non-GAAP R&D expenses for the third quarter of 2023 were $1.5 billion compared to $1.2 billion in the same period in 2022. The increases in GAAP and non-GAAP R&D expenses were primarily driven by increased clinical activity, as well as costs associated with the discontinuation of two Phase 3 magrolimab studies.
•Acquired in-process research and development (“IPR&D”) expenses for the third quarter of 2023 were $91 million, driven by an upfront payment related to the Tentarix Biotherapeutics Inc. (“Tentarix”) collaboration and other collaboration-related activities.
•Selling, general and administrative (“SG&A”) expenses and non-GAAP SG&A expenses for the third quarter of 2023 were $1.3 billion compared to $1.2 billion in the same period in 2022. The increases in GAAP and non-GAAP SG&A expenses were primarily driven by increased commercial activities in Oncology.
•The effective tax rate (“ETR”) for the third quarter of 2023 was 6.3% compared to 26.6% for the same period in 2022, and non-GAAP ETR for the third quarter of 2023 was 7.0% compared to 22.4% for the same period in 2022. Both ETR and non-GAAP ETR decreases were primarily driven by a decrease in tax reserves as a result of reaching agreement with a tax authority on certain tax positions.
Guidance and Outlook
For the full-year, Gilead expects:
•Total product sales between $26.7 billion and $26.9 billion, compared to $26.3 billion and $26.7 billion previously.
•Total product sales, excluding Veklury, between $24.8 billion and $25.0 billion, compared to $24.6 billion and $25.0 billion previously.
•Total Veklury sales of approximately $1.9 billion, compared to approximately $1.7 billion previously.
•Diluted earnings per share between $4.55 and $4.75, compared to $4.50 and $4.85 previously.
•Non-GAAP diluted earnings per share between $6.65 and $6.85, compared to $6.45 and $6.80 previously.
Additional information and a reconciliation between GAAP and non-GAAP financial information for the 2023 guidance is provided in the accompanying tables. Also see the Forward-Looking Statements described below. The financial guidance is subject to a number of risks and uncertainties, including uncertainty around the duration and magnitude of the COVID-19 pandemic.
Key Updates Since Our Last Quarterly Release
Virology
•Received U.S. Food and Drug Administration (“FDA”) and European Commission approval to extend the use of Veklury to treat COVID-19 in appropriate patients with mild to severe hepatic impairment.
•Presented new data at the European AIDS Conference 2023, including three-year outcomes from BICSTaR, an ongoing real-world study evaluating Biktarvy in people with HIV who have a high burden of co-morbidities, and multiple analyses from the Phase 2/3 CAPELLA study of lenacapavir in people with multi-drug resistant HIV.
•Announced PURPOSE 5, a Phase 2 clinical trial to assess the persistence of lenacapavir compared with FTC/tenofovir disoproxil fumarate in people who may benefit from PrEP in Europe. The use of lenacapavir for PrEP is investigational.
•Presented new data at Infectious Disease Week 2023 demonstrating Biktarvy’s efficacy and safety profile across a broad range of people with HIV as well as two-year outcomes from the CAPELLA study of lenacapavir. Additionally, presented data on the safety profile of Veklury across vulnerable populations and the drug-drug interaction profile of the investigational oral antiviral obeldesivir, as well as new in vitro data on antiviral activity of Veklury and obeldesivir against recent SARS-CoV-2 Omicron subvariants.
•Discontinued the Phase 3 BIRCH trial of obeldesivir in non-hospitalized participants who are at high risk for developing severe COVID-19. The decision was based on lower-than-expected COVID-19 incidence rates and related hospitalizations or all-cause death by Day 29, and does not reflect any safety or efficacy concerns.
•Announced the Phase 3 OAKTREE trial of obeldesivir in non-hospitalized participants without risk factors for developing severe COVID-19 is approaching full enrollment, and remains unaffected by the BIRCH decision.
•Announced plans to present at the American Association for the Study of Liver Diseases 2023 annual meeting. Presentations will include new and long-term data across Gilead’s Liver Disease portfolio.
•Announced a collaboration with Assembly Biosciences, Inc. (“Assembly”) to advance the research and development of novel antiviral therapies, including in herpesviruses, HBV and HDV.
Oncology
•Presented promising early data at the 2023 World Conference on Lung Cancer from the Phase 2 EVOKE-02 study evaluating the investigational use of Trodelvy in combination with Keytruda® (pembrolizumab) as a first-line treatment in patients with advanced or metastatic non-small cell lung cancer without actionable genomic alterations. The study demonstrated clinical activity in patients with PD-L1 tumor proportion score (“TPS”) >50% in Cohort A and PD-L1 TPS<50% in Cohort B, including early and durable responses, as well as safety consistent with the known safety profile of each agent.
•Presented data at the European Society of Medical Oncology 2023 meeting from the Phase 2 TROPiCS-03 basket study demonstrating encouraging activity of Trodelvy for investigational use in both advanced head and neck squamous cell carcinoma and extensive stage small cell lung cancer cohorts, as well as other data in breast and urothelial cancer. Additionally, presented a comparative analysis, adjusting for trial differences, on Yescarta relative to bispecific antibodies in 3L+ R/R LBCL.
•Announced abstracts for the American Society of Hematology 2023 Annual Meeting, including updated Phase 1 data evaluating the Arcellx, Inc. (“Arcellx”) partnered CART-ddBCMA in R/R multiple myeloma, demonstrating continued deep and durable responses with 22 months follow-up. Additionally announced abstracts for long-term follow-up across Yescarta trials in R/R LBCL, first-line high-risk LBCL, and R/R follicular lymphoma, as well as real-world data for Tecartus in R/R MCL and B-cell ALL.
•Announced results from the Phase 2 ALYCANTE study, led and sponsored by the French collaborative group LYSA/LYSARC, evaluating Yescarta in transplant-ineligible patients with second-line R/R LBCL, which demonstrated high response rates and durable remission.
•Presented initial data, alongside Arcus Biosciences, Inc. (“Arcus”) at the American Society of Clinical Oncology Monthly Plenary Session from the Phase 2 EDGE-Gastric study of domvanalimab in combination with zimberelimab and chemotherapy in first-line locally advanced unresectable or metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma. The results showed encouraging overall response rates and six-month landmark progression-free survival rate.
•Discontinued the Phase 3 ENHANCE-2 study of magrolimab in first-line acute myeloid leukemia (“AML”) with TP53 mutations based on an ad hoc analysis and following review by an independent data monitoring committee. Additionally announced that the U.S. FDA placed a partial clinical hold on magrolimab studies in AML that paused enrollment, though previously enrolled patients may continue to receive the study medicine.
•Announced a collaboration with Tentarix to discover and develop novel therapies across oncology and inflammation, using Tentarix’s proprietary Tentacles platform.
•Announced a collaboration with Epicrispr Biotechnologies, Inc. (“Epic Bio”) to develop next-generation cancer cell therapies using Epic Bio’s proprietary gene regulation platform.
Corporate
•Issued $2.0 billion aggregate principal amount of senior unsecured notes in a registered offering, comprised of $1.0 billion principal amount of 5.25% senior notes due in 2033 and $1.0 billion principal amount of 5.55% senior notes due in 2053, and repaid debt of $2.3 billion.
•The company’s Board of Directors declared a quarterly dividend of $0.75 per share of common stock for the fourth quarter of 2023. The dividend is payable on December 28, 2023, to stockholders of record at the close of business on December 15, 2023. Future dividends will be subject to Board approval.
Certain amounts and percentages in this press release may not sum or recalculate due to rounding.
Conference Call
At 1:30 p.m. Pacific Time today, Gilead will host a conference call to discuss Gilead’s results. A live webcast will be available on http://investors.gilead.com and will be archived on www.gilead.com for one year.
Non-GAAP Financial Information
The information presented in this document has been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”), unless otherwise noted as non-GAAP. Management believes non-GAAP information is useful for investors, when considered in conjunction with Gilead’s GAAP financial information, because management uses such information internally for its operating, budgeting and financial planning purposes. Non-GAAP information is not prepared under a comprehensive set of accounting rules and should only be used to supplement an understanding of Gilead’s operating results as reported under GAAP. Non-GAAP financial information generally excludes acquisition-related expenses including amortization of acquired intangible assets and inventory step-up charges, and other items that are considered unusual or not representative of underlying trends of Gilead’s business, fair value adjustments of equity securities and discrete and related tax charges or benefits associated with changes in tax related laws and guidelines. Although Gilead consistently excludes the amortization of acquired intangible assets from the non-GAAP financial information, management believes that it is important for investors to understand that such intangible assets were recorded as part of acquisitions and contribute to ongoing revenue generation. Non-GAAP measures may be defined and calculated differently by other companies in the same industry. Reconciliations of the non-GAAP financial measures to the most directly comparable GAAP financial measures are provided in the accompanying tables.
About Gilead Sciences
Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. The company is committed to advancing innovative medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis, COVID-19 and cancer. Gilead operates in more than 35 countries worldwide, with headquarters in Foster City, California.
Forward-Looking Statements
Statements included in this press release that are not historical in nature are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Gilead cautions readers that forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially. These risks and uncertainties include those relating to: Gilead’s ability to achieve its anticipated full year 2023 financial results, including as a result of the uncertainty of the amount and timing of Veklury revenues; Gilead’s ability to make progress on any of its long-term ambitions or strategic priorities laid out in its corporate strategy; Gilead’s ability to accelerate or sustain revenues for its virology, oncology and other programs; Gilead’s ability to realize the potential benefits of acquisitions, collaborations or licensing arrangements, including the arrangements with Arcus, Arcellx, Assembly, Epic Bio, and Tentarix; patent protection and estimated loss of exclusivity for our products and product candidates; Gilead’s ability to initiate, progress or complete clinical trials within currently anticipated timeframes or at all, the possibility of unfavorable results from ongoing and additional clinical trials, including those involving Biktarvy, Tecartus, Trodelvy, Veklury, Yescarta, CART-ddBCMA, domvanalimab, lenacapavir, magrolimab, obeldesivir, and zimberelimab, and the risk that safety and efficacy data from clinical trials may not warrant further development of Gilead’s product candidates or the product candidates of Gilead’s strategic partners; Gilead’s ability to submit new drug applications for new product candidates or expanded indications in the currently anticipated timelines; Gilead’s ability to receive regulatory approvals in a timely manner or at all, and the risk that any such approvals, if granted, may be subject to significant limitations on use; Gilead’s ability to successfully commercialize its products; the risk of potential disruptions to the manufacturing and supply chain of Gilead’s products; pricing and reimbursement pressures from government agencies and other third parties, including required rebates and other discounts; a larger than anticipated shift in payer mix to more highly discounted payer segments; market share and price erosion caused by the introduction of generic versions of
Gilead products; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products, including Veklury; and other risks identified from time to time in Gilead’s reports filed with the SEC, including annual reports on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K. In addition, Gilead makes estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses and related disclosures. Gilead bases its estimates on historical experience and on various other market specific and other relevant assumptions that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. There may be other factors of which Gilead is not currently aware that may affect matters discussed in the forward-looking statements and may also cause actual results to differ significantly from these estimates. Further, results for the quarter ended September 30, 2023 are not necessarily indicative of operating results for any future periods. Gilead directs readers to its press releases, annual reports on Form 10-K, quarterly reports on Form 10-Q and other subsequent disclosure documents filed with the SEC. Gilead claims the protection of the Safe Harbor contained in the Private Securities Litigation Reform Act of 1995 for forward-looking statements.
The reader is cautioned that forward-looking statements are not guarantees of future performance and is cautioned not to place undue reliance on these forward-looking statements. All forward-looking statements are based on information currently available to Gilead and Gilead assumes no obligation to update or supplement any such forward-looking statements other than as required by law. Any forward-looking statements speak only as of the date hereof or as of the dates indicated in the statements.
# # #
Gilead owns or has rights to various trademarks, copyrights and trade names used in its business, including the following: GILEAD®, GILEAD SCIENCES®, KITETM, AMBISOME®, ATRIPLA®, BIKTARVY®, CAYSTON®, COMPLERA®, DESCOVY®, DESCOVY FOR PREP®, EMTRIVA®, EPCLUSA®, EVIPLERA®, GENVOYA®, HARVONI®, HEPCLUDEX®, HEPSERA®, JYSELECA®, LETAIRIS®, ODEFSEY®, RANEXA®, SOVALDI®, STRIBILD®, SUNLENCA® , TECARTUS®, TRODELVY®, TRUVADA®, TRUVADA FOR PREP®, TYBOST®, VEKLURY®, VEMLIDY®, VIREAD®, VOSEVI®, YESCARTA® and ZYDELIG®. KEYTRUDA® is a registered trademark of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, United States. Other trademarks are the property of their respective owners.
For more information on Gilead Sciences, Inc., please visit www.gilead.com or call the Gilead Public Affairs Department at 1-800-GILEAD-5 (1-800-445-3235).
| | | | | | | | | | | | | | | | | |
| CONTACTS: | Investors: | Jacquie Ross, CFA | investor_relations@gilead.com | |
| | Media: | Ashleigh Koss | public_affairs@gilead.com | |
GILEAD SCIENCES, INC.
CONDENSED CONSOLIDATED STATEMENTS OF INCOME
(unaudited)
| | | | | | | | | | | | | | | | | | | | | | | | | | |
| | Three Months Ended | | Nine Months Ended |
| | September 30, | | September 30, |
| (in millions, except per share amounts) | | 2023 | | 2022 | | 2023 | | 2022 |
| Revenues: | | | | | | | | |
| Product sales | | $ | 6,994 | | | $ | 6,978 | | | $ | 19,864 | | | $ | 19,650 | |
| Royalty, contract and other revenues | | 56 | | | 64 | | | 138 | | | 242 | |
| Total revenues | | 7,051 | | | 7,042 | | | 20,002 | | | 19,892 | |
| Costs and expenses: | | | | | | | | |
| Cost of goods sold | | 1,565 | | | 1,395 | | | 4,408 | | | 4,261 | |
| Research and development expenses | | 1,457 | | | 1,149 | | | 4,310 | | | 3,429 | |
| Acquired in-process research and development expenses | | 91 | | | 448 | | | 808 | | | 786 | |
| In-process research and development impairment | | — | | | — | | | — | | | 2,700 | |
| Selling, general and administrative expenses | | 1,315 | | | 1,213 | | | 4,482 | | | 3,653 | |
| Total costs and expenses | | 4,428 | | | 4,205 | | | 14,009 | | | 14,829 | |
| Operating income | | 2,623 | | | 2,837 | | | 5,993 | | | 5,063 | |
| Interest expense | | (232) | | | (229) | | | (692) | | | (709) | |
| Other income (expense), net | | (72) | | | (176) | | | (95) | | | (571) | |
| Income before income taxes | | 2,318 | | | 2,432 | | | 5,206 | | | 3,783 | |
| Income tax expense | | (146) | | | (646) | | | (1,010) | | | (850) | |
| Net income | | 2,172 | | | 1,786 | | | 4,196 | | | 2,933 | |
| Net loss attributable to noncontrolling interest | | 8 | | | 3 | | | 40 | | | 19 | |
| Net income attributable to Gilead | | $ | 2,180 | | | $ | 1,789 | | | $ | 4,236 | | | $ | 2,952 | |
| Basic earnings per share attributable to Gilead | | $ | 1.75 | | | $ | 1.43 | | | $ | 3.39 | | | $ | 2.35 | |
| Shares used in basic earnings per share attributable to Gilead calculation | | 1,248 | | | 1,255 | | | 1,249 | | | 1,255 | |
| Diluted earnings per share attributable to Gilead | | $ | 1.73 | | | $ | 1.42 | | | $ | 3.37 | | | $ | 2.34 | |
| Shares used in diluted earnings per share attributable to Gilead calculation | | 1,257 | | | 1,261 | | | 1,259 | | | 1,261 | |
| Cash dividends declared per share | | $ | 0.75 | | | $ | 0.73 | | | $ | 2.25 | | | $ | 2.19 | |
| | | | | | | | |
| Research and development expenses as a % of revenues | | 20.7 | % | | 16.3 | % | | 21.5 | % | | 17.2 | % |
| Selling, general and administrative expenses as a % of revenues | | 18.6 | % | | 17.2 | % | | 22.4 | % | | 18.4 | % |
GILEAD SCIENCES, INC.
TOTAL REVENUE SUMMARY
(unaudited)
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | Three Months Ended | | | | Nine Months Ended | | |
| | September 30, | | | | September 30, | | |
| (in millions, except percentages) | | 2023 | | 2022 | | Change | | 2023 | | 2022 | | Change |
| Product sales: | | | | | | | | | | | | |
| HIV | | $ | 4,667 | | | $ | 4,487 | | | 4% | | $ | 13,482 | | | $ | 12,422 | | | 9% |
| Oncology | | 769 | | | 578 | | | 33% | | 2,167 | | | 1,525 | | | 42% |
Liver Disease | | 706 | | | 788 | | | (10)% | | 2,093 | | | 2,104 | | | (1)% |
| Other | | 216 | | | 200 | | | 8% | | 658 | | | 693 | | | (5)% |
| Total product sales excluding Veklury | | 6,358 | | | 6,053 | | | 5% | | 18,400 | | | 16,745 | | | 10% |
| Veklury | | 636 | | | 925 | | | (31)% | | 1,465 | | | 2,905 | | | (50)% |
| Total product sales | | 6,994 | | | 6,978 | | | —% | | 19,864 | | | 19,650 | | | 1% |
| Royalty, contract and other revenues | | 56 | | | 64 | | | (13)% | | 138 | | | 242 | | | (43)% |
| Total revenues | | $ | 7,051 | | | $ | 7,042 | | | —% | | $ | 20,002 | | | $ | 19,892 | | | 1% |
GILEAD SCIENCES, INC.
NON-GAAP FINANCIAL INFORMATION(1)
(unaudited)
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | Three Months Ended | | | | Nine Months Ended | | |
| | September 30, | | | | September 30, | | |
| (in millions, except percentages) | | 2023 | | 2022 | | Change | | 2023 | | 2022 | | Change |
| Non-GAAP: | | | | | | | | | | | | |
| Cost of goods sold | | $ | 985 | | | $ | 923 | | | 7% | | $ | 2,717 | | | $ | 2,634 | | | 3% |
| Research and development expenses | | $ | 1,453 | | | $ | 1,173 | | | 24% | | $ | 4,268 | | | $ | 3,425 | | | 25% |
| Acquired IPR&D expenses | | $ | 91 | | | $ | 448 | | | (80)% | | $ | 808 | | | $ | 786 | | | 3% |
| Selling, general and administrative expenses | | $ | 1,298 | | | $ | 1,212 | | | 7% | | $ | 4,464 | | | $ | 3,566 | | | 25% |
| Other income (expense), net | | $ | 96 | | | $ | 20 | | | NM | | $ | 261 | | | $ | 25 | | | NM |
| Diluted EPS | | $ | 2.29 | | | $ | 1.90 | | | 21% | | $ | 5.00 | | | $ | 5.59 | | | (11)% |
| | | | | | | | | | | | |
| Product gross margin | | 85.9 | % | | 86.8 | % | | -85 bps | | 86.3 | % | | 86.6 | % | | -27 bps |
| Research and development expenses as a % of revenues | | 20.6 | % | | 16.7 | % | | 394 bps | | 21.3 | % | | 17.2 | % | | 412 bps |
| Selling, general and administrative expenses as a % of revenues | | 18.4 | % | | 17.2 | % | | 120 bps | | 22.3 | % | | 17.9 | % | | 439 bps |
| Operating margin | | 45.7 | % | | 46.7 | % | | -92 bps | | 38.7 | % | | 47.7 | % | | -894 bps |
| Effective tax rate | | 7.0 | % | | 22.4 | % | | -1540 bps | | 14.5 | % | | 20.1 | % | | -555 bps |
________________________________
NM - Not Meaningful
(1) Refer to Non-GAAP Financial Information section above for further disclosures on non-GAAP financial measures. A reconciliation between GAAP and non-GAAP financial information is provided in the tables below.
GILEAD SCIENCES, INC.
RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL INFORMATION
(unaudited)
| | | | | | | | | | | | | | | | | | | | | | | | | | |
| | Three Months Ended | | Nine Months Ended |
| | September 30, | | September 30, |
| (in millions, except percentages and per share amounts) | | 2023 | | 2022 | | 2023 | | 2022 |
| Cost of goods sold reconciliation: | | | | | | | | |
| GAAP cost of goods sold | | $ | 1,565 | | | $ | 1,395 | | | $ | 4,408 | | | $ | 4,261 | |
Acquisition-related – amortization(1) | | (581) | | | (472) | | | (1,691) | | | (1,585) | |
Other(2) | | — | | | — | | | — | | | (42) | |
| Non-GAAP cost of goods sold | | $ | 985 | | | $ | 923 | | | $ | 2,717 | | | $ | 2,634 | |
| | | | | | | | |
| Product gross margin reconciliation: | | | | | | | | |
| GAAP product gross margin | | 77.6 | % | | 80.0 | % | | 77.8 | % | | 78.3 | % |
Acquisition-related – amortization(1) | | 8.3 | % | | 6.8 | % | | 8.5 | % | | 8.1 | % |
Other(2) | | — | % | | — | % | | — | % | | 0.2 | % |
| Non-GAAP product gross margin | | 85.9 | % | | 86.8 | % | | 86.3 | % | | 86.6 | % |
| | | | | | | | |
| Research and development expenses reconciliation: | | | | | | | | |
| GAAP research and development expenses | | $ | 1,457 | | | $ | 1,149 | | | $ | 4,310 | | | $ | 3,429 | |
Acquisition-related – other costs(3) | | 1 | | | 24 | | | (37) | | | 13 | |
Other(2) | | (5) | | | — | | | (5) | | | (18) | |
| Non-GAAP research and development expenses | | $ | 1,453 | | | $ | 1,173 | | | $ | 4,268 | | | $ | 3,425 | |
| | | | | | | | |
| IPR&D impairment reconciliation: | | | | | | | | |
| GAAP IPR&D impairment | | $ | — | | | $ | — | | | $ | — | | | $ | 2,700 | |
| IPR&D impairment | | — | | | — | | | — | | | (2,700) | |
| Non-GAAP IPR&D impairment | | $ | — | | | $ | — | | | $ | — | | | $ | — | |
| | | | | | | | |
| Selling, general and administrative expenses reconciliation: | | | | | | | | |
| GAAP selling, general and administrative expenses | | $ | 1,315 | | | $ | 1,213 | | | $ | 4,482 | | | $ | 3,653 | |
Acquisition-related – other costs(3) | | — | | | (2) | | | (2) | | | (2) | |
Other(2) | | (17) | | | 1 | | | (17) | | | (84) | |
| Non-GAAP selling, general and administrative expenses | | $ | 1,298 | | | $ | 1,212 | | | $ | 4,464 | | | $ | 3,566 | |
| | | | | | | | |
| Operating income reconciliation: | | | | | | | | |
| GAAP operating income | | $ | 2,623 | | | $ | 2,836 | | | $ | 5,993 | | | $ | 5,063 | |
Acquisition-related – amortization(1) | | 581 | | | 472 | | | 1,691 | | | 1,585 | |
Acquisition-related – other costs(3) | | (1) | | | (22) | | | 39 | | | (11) | |
| IPR&D impairment | | — | | | — | | | — | | | 2,700 | |
Other(2) | | 22 | | | (1) | | | 22 | | | 144 | |
| Non-GAAP operating income | | $ | 3,224 | | | $ | 3,286 | | | $ | 7,745 | | | $ | 9,480 | |
| | | | | | | | |
| Operating margin reconciliation: | | | | | | | | |
| GAAP operating margin | | 37.2 | % | | 40.3 | % | | 30.0 | % | | 25.5 | % |
Acquisition-related – amortization(1) | | 8.2 | % | | 6.7 | % | | 8.5 | % | | 8.0 | % |
Acquisition-related – other costs(3) | | — | % | | (0.3) | % | | 0.2 | % | | (0.1) | % |
| IPR&D impairment | | — | % | | — | % | | — | % | | 13.6 | % |
Other(2) | | 0.3 | % | | — | % | | 0.1 | % | | 0.7 | % |
| Non-GAAP operating margin | | 45.7 | % | | 46.7 | % | | 38.7 | % | | 47.7 | % |
| | | | | | | | |
| Other income (expense), net reconciliation: | | | | | | | | |
| GAAP other income (expense), net | | $ | (72) | | | $ | (176) | | | $ | (95) | | | $ | (571) | |
| Loss from equity securities, net | | 168 | | | 197 | | | 356 | | | 596 | |
| Non-GAAP other income (expense), net | | $ | 96 | | | $ | 20 | | | $ | 261 | | | $ | 25 | |
| | | | | | | | |
GILEAD SCIENCES, INC.
RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL INFORMATION - (Continued)
(unaudited)
| | | | | | | | | | | | | | | | | | | | | | | | | | |
| | Three Months Ended | | Nine Months Ended |
| | September 30, | | September 30, |
| (in millions, except percentages and per share amounts) | | 2023 | | 2022 | | 2023 | | 2022 |
| Effective tax rate reconciliation: | | | | | | | | |
| GAAP effective tax rate | | 6.3 | % | | 26.6 | % | | 19.4 | % | | 22.5 | % |
Income tax effect of above non-GAAP adjustments and discrete and related tax adjustments(4) | | 0.7 | % | | (4.1) | % | | (4.9) | % | | (2.4) | % |
| Non-GAAP effective tax rate | | 7.0 | % | | 22.4 | % | | 14.5 | % | | 20.1 | % |
| | | | | | | | |
| Net income attributable to Gilead reconciliation: | | | | | | | | |
| GAAP net income attributable to Gilead | | $ | 2,180 | | | $ | 1,789 | | | $ | 4,236 | | | $ | 2,952 | |
Acquisition-related – amortization(1) | | 461 | | | 379 | | | 1,345 | | | 1,264 | |
Acquisition-related – other costs(3) | | (1) | | | (23) | | | 31 | | | (13) | |
| IPR&D impairment | | — | | | — | | | — | | | 2,057 | |
| Loss from equity securities, net | | 164 | | | 198 | | | 351 | | | 570 | |
Discrete and related tax charges(4) | | 58 | | | 49 | | | 314 | | | 118 | |
Other(2) | | 17 | | | — | | | 17 | | | 104 | |
| Non-GAAP net income attributable to Gilead | | $ | 2,879 | | | $ | 2,391 | | | $ | 6,293 | | | $ | 7,052 | |
| | | | | | | | |
| Diluted earnings per share reconciliation: | | | | | | | | |
| GAAP diluted earnings per share | | $ | 1.73 | | | $ | 1.42 | | | $ | 3.37 | | | $ | 2.34 | |
Acquisition-related – amortization(1) | | 0.37 | | | 0.30 | | | 1.07 | | | 1.00 | |
Acquisition-related – other costs(3) | | — | | | (0.02) | | | 0.02 | | | (0.01) | |
| IPR&D impairment | | — | | | — | | | — | | | 1.63 | |
| Loss from equity securities, net | | 0.13 | | | 0.16 | | | 0.28 | | | 0.45 | |
Discrete and related tax charges(4) | | 0.05 | | | 0.04 | | | 0.25 | | | 0.09 | |
Other(2) | | 0.01 | | | — | | | 0.01 | | | 0.08 | |
| Non-GAAP diluted earnings per share | | $ | 2.29 | | | $ | 1.90 | | | $ | 5.00 | | | $ | 5.59 | |
| | | | | | | | |
| Non-GAAP adjustment summary: | | | | | | | | |
| Cost of goods sold adjustments | | $ | 581 | | | $ | 472 | | | $ | 1,691 | | | $ | 1,627 | |
| Research and development expenses adjustments | | 4 | | | (24) | | | 42 | | | 5 | |
| IPR&D impairment adjustments | | — | | | — | | | — | | | 2,700 | |
| Selling, general and administrative expenses adjustments | | 17 | | | 1 | | | 19 | | | 86 | |
Total non-GAAP adjustments to costs and expenses | | 602 | | | 450 | | | 1,752 | | | 4,418 | |
| Other income (expense), net, adjustments | | 168 | | | 197 | | | 356 | | | 596 | |
| Total non-GAAP adjustments before income taxes | | 770 | | | 646 | | | 2,108 | | | 5,014 | |
| Income tax effect of non-GAAP adjustments above | | (129) | | | (93) | | | (364) | | | (1,032) | |
Discrete and related tax charges(4) | | 58 | | | 49 | | | 314 | | | 118 | |
| Total non-GAAP adjustments after tax | | $ | 699 | | | $ | 602 | | | $ | 2,057 | | | $ | 4,100 | |
______________________________(1) Relates to amortization of acquired intangibles and inventory step-up charges.
(2) Adjustments to Cost of goods sold and Research and development expenses primarily include various restructuring expenses during the first quarter of 2022 and third quarter of 2023. Adjustments to Selling, general and administrative expenses include donations to the Gilead Foundation, a California nonprofit organization, during the second quarter of 2022 and various restructuring expenses during the third quarter of 2023.
(3) Adjustments include employee-related expenses, contingent consideration fair value adjustments and other expenses associated with Gilead’s acquisitions of MYR GmbH, MiroBio, Ltd., Tmunity Therapeutics, Inc. and XinThera, Inc.
(4) Represents discrete and related deferred tax charges or benefits primarily associated with acquired intangible assets and transfers of intangible assets from a foreign subsidiary to Ireland and the United States.
GILEAD SCIENCES, INC.
RECONCILIATION OF GAAP TO NON-GAAP 2023 FULL-YEAR GUIDANCE(1)
(unaudited)
| | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | |
| (in millions, except percentages and per share amounts) | | Provided
February 2, 2023 | | Updated
April 27, 2023 | | Updated
August 3, 2023 | | Updated
November 7, 2023 |
| Projected product gross margin GAAP to non-GAAP reconciliation: | | | | | | | | |
| GAAP projected product gross margin | | 79.0% | | 77.0% | | 77.0% | | 77.0% |
| Acquisition-related expenses and other | | ~ 7% | | ~ 9% | | ~ 9% | | ~ 9% |
| Non-GAAP projected product gross margin | | 86.0% | | 86.0% | | 86.0% | | 86.0% |
| | | | | | | | |
| Projected operating income GAAP to non-GAAP reconciliation: | | | | | | | | |
| GAAP projected operating income | | $9,200 - $9,800 | | $8,600 - $9,200 | | $8,000 - $8,500 | | $8,100 - $8,400 |
| Acquisition-related expenses and other | | ~ 1,800 | | ~ 2,400 | | ~ 2,400 | | ~ 2,400 |
| Non-GAAP projected operating income | | $11,000 - $11,600 | | $11,000 - $11,600 | | $10,400 - $10,900 | | $10,500 - $10,800 |
| | | | | | | | |
| Projected effective tax rate GAAP to non-GAAP reconciliation: | | | | | | | | |
| GAAP projected effective tax rate | | ~ 22% | | ~ 22% | | ~ 21% | | ~ 20% |
| Discrete and related tax adjustments, and income tax effect of adjustments above and fair value adjustments of equity securities | | (~ 2%) | | (~ 2%) | | (~ 4%) | | (~ 4%) |
| Non-GAAP projected effective tax rate | | ~ 20% | | ~ 20% | | ~ 17% | | ~ 16% |
| | | | | | | | |
| Projected diluted EPS GAAP to non-GAAP reconciliation: | | | | | | | | |
| GAAP projected diluted EPS | | $5.30 - $5.70 | | $4.75 - $5.15 | | $4.50 - $4.85 | | $4.55 - $4.75 |
| Acquisition-related expenses, fair value adjustments of equity securities, discrete and related tax adjustments and other | | ~ 1.30 | | ~ 1.85 | | ~ 1.95 | | ~ 2.10 |
| Non-GAAP projected diluted EPS | | $6.60 - $7.00 | | $6.60 - $7.00 | | $6.45 - $6.80 | | $6.65 - $6.85 |
________________________________
(1) Our full-year guidance excludes the potential impact of any (i) acquisitions or business development transactions that have not been executed, (ii) future fair value adjustments of equity securities and (iii) discrete tax charges or benefits associated with changes in tax related laws and guidelines that have not been enacted, as Gilead is unable to project such amounts. The non-GAAP full-year guidance includes non-GAAP adjustments to actual current period results as well as adjustments for the known future impact associated with events that have already occurred, such as future amortization of our intangible assets and the future impact of discrete and related deferred tax charges or benefits primarily associated with acquired intangible assets and transfers of intangible assets from a foreign subsidiary to Ireland and the United States.
GILEAD SCIENCES, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(unaudited)
| | | | | | | | | | | | | | |
| | September 30, | | December 31, |
| (in millions) | | 2023 | | 2022 |
| Assets | | | | |
| Cash, cash equivalents and marketable debt securities | | $ | 8,021 | | | $ | 7,630 | |
| Accounts receivable, net | | 4,790 | | | 4,777 | |
| Inventories | | 3,202 | | | 2,820 | |
| Property, plant and equipment, net | | 5,572 | | | 5,475 | |
| Intangible assets, net | | 27,152 | | | 28,894 | |
| Goodwill | | 8,314 | | | 8,314 | |
| Other assets | | 5,323 | | | 5,262 | |
| Total assets | | $ | 62,373 | | | $ | 63,171 | |
| Liabilities and Stockholders’ Equity | | | | |
| Current liabilities | | $ | 11,945 | | | $ | 11,237 | |
| Long-term liabilities | | 28,186 | | | 30,725 | |
Stockholders’ equity(1) | | 22,242 | | | 21,209 | |
| Total liabilities and stockholders’ equity | | $ | 62,373 | | | $ | 63,171 | |
________________________________
(1) As of September 30, 2023 and December 31, 2022, there were 1,247 shares of common stock issued and outstanding.
GILEAD SCIENCES, INC.
SELECTED CASH FLOW INFORMATION
(unaudited)
| | | | | | | | | | | | | | | | | | | | | | | | | | |
| | Three Months Ended | | Nine Months Ended |
| | September 30, | | September 30, |
| (in millions) | | 2023 | | 2022 | | 2023 | | 2022 |
| Net cash provided by operating activities | | $ | 1,756 | | | $ | 2,863 | | | $ | 5,837 | | | $ | 6,505 | |
| Net cash used in investing activities | | (229) | | | (713) | | | (1,538) | | | (2,091) | |
| Net cash used in financing activities | | (1,518) | | | (2,118) | | | (4,026) | | | (4,915) | |
| Effect of exchange rate changes on cash and cash equivalents | | (7) | | | (72) | | | 20 | | | (138) | |
| Net change in cash and cash equivalents | | 1 | | | (40) | | | 293 | | | (639) | |
| Cash and cash equivalents at beginning of period | | 5,704 | | | 4,739 | | | 5,412 | | | 5,338 | |
| Cash and cash equivalents at end of period | | $ | 5,705 | | | $ | 4,699 | | | $ | 5,705 | | | $ | 4,699 | |
| | | | | | | | | | | | | | | | | | | | | | | | | | |
| | Three Months Ended | | Nine Months Ended |
| | September 30, | | September 30, |
| (in millions) | | 2023 | | 2022 | | 2023 | | 2022 |
| Net cash provided by operating activities | | $ | 1,756 | | | $ | 2,863 | | | $ | 5,837 | | | $ | 6,505 | |
| Capital expenditures | | (122) | | | (157) | | | (370) | | | (547) | |
Free cash flow(1) | | $ | 1,633 | | | $ | 2,706 | | | $ | 5,467 | | | $ | 5,958 | |
________________________________
(1) Free cash flow is a non-GAAP liquidity measure. Please refer to our disclosures in the Non-GAAP Financial Information section above.
GILEAD SCIENCES, INC.
PRODUCT SALES SUMMARY
(unaudited)
| | | | | | | | | | | | | | | | | | | | | | | | | | |
| | Three Months Ended | | Nine Months Ended |
| | September 30, | | September 30, |
| (in millions) | | 2023 | | 2022 | | 2023 | | 2022 |
| HIV | | | | | | | | |
| Biktarvy – U.S. | | $ | 2,504 | | | $ | 2,286 | | | $ | 7,104 | | | $ | 6,088 | |
| Biktarvy – Europe | | 313 | | | 278 | | | 920 | | | 807 | |
| Biktarvy – Other International | | 268 | | | 201 | | | 717 | | | 577 | |
| | 3,085 | | | 2,766 | | | 8,741 | | | 7,472 | |
| | | | | | | | |
| Complera / Eviplera – U.S. | | 13 | | | 20 | | | 40 | | | 56 | |
| Complera / Eviplera – Europe | | 18 | | | 21 | | | 55 | | | 76 | |
| Complera / Eviplera – Other International | | 3 | | | 3 | | | 9 | | | 10 | |
| | 34 | | | 43 | | | 104 | | | 142 | |
| | | | | | | | |
| Descovy – U.S. | | 460 | | | 444 | | | 1,314 | | | 1,152 | |
| Descovy – Europe | | 25 | | | 28 | | | 75 | | | 92 | |
| Descovy – Other International | | 26 | | | 28 | | | 86 | | | 91 | |
| | 511 | | | 500 | | | 1,475 | | | 1,335 | |
| | | | | | | | |
| Genvoya – U.S. | | 433 | | | 502 | | | 1,305 | | | 1,441 | |
| Genvoya – Europe | | 47 | | | 71 | | | 157 | | | 220 | |
| Genvoya – Other International | | 23 | | | 27 | | | 81 | | | 103 | |
| | 503 | | | 600 | | | 1,544 | | | 1,764 | |
| | | | | | | | |
| Odefsey – U.S. | | 257 | | | 276 | | | 754 | | | 763 | |
| Odefsey – Europe | | 74 | | | 86 | | | 223 | | | 278 | |
| Odefsey – Other International | | 11 | | | 12 | | | 33 | | | 36 | |
| | 343 | | | 374 | | | 1,011 | | | 1,077 | |
| | | | | | | | |
| Stribild – U.S. | | 18 | | | 22 | | | 57 | | | 68 | |
| Stribild – Europe | | 5 | | | 7 | | | 16 | | | 23 | |
| Stribild – Other International | | 2 | | | 3 | | | 6 | | | 7 | |
| | 25 | | | 32 | | | 79 | | | 98 | |
| | | | | | | | |
| Truvada – U.S. | | 15 | | | 24 | | | 71 | | | 77 | |
| Truvada – Europe | | 3 | | | 3 | | | 10 | | | 12 | |
| Truvada – Other International | | 4 | | | 2 | | | 16 | | | 13 | |
| | 22 | | | 30 | | | 97 | | | 102 | |
| | | | | | | | |
Revenue share – Symtuza(1) – U.S. | | 96 | | | 85 | | | 278 | | | 251 | |
Revenue share – Symtuza(1) – Europe | | 32 | | | 40 | | | 101 | | | 126 | |
Revenue share – Symtuza(1) – Other International | | 3 | | | 4 | | | 10 | | | 10 | |
| | 131 | | | 130 | | | 390 | | | 388 | |
| | | | | | | | |
Other HIV(2) – U.S. | | 10 | | | 1 | | | 24 | | | 11 | |
Other HIV(2) – Europe | | 3 | | | 6 | | | 11 | | | 20 | |
Other HIV(2) – Other International | | — | | | 5 | | | 6 | | | 15 | |
| | 13 | | | 12 | | | 41 | | | 45 | |
| | | | | | | | |
| Total HIV – U.S. | | 3,807 | | | 3,661 | | | 10,949 | | | 9,906 | |
| Total HIV – Europe | | 519 | | | 541 | | | 1,568 | | | 1,653 | |
| Total HIV – Other International | | 341 | | | 285 | | | 965 | | | 863 | |
| | $ | 4,667 | | | $ | 4,487 | | | $ | 13,482 | | | $ | 12,422 | |
| | | | | | | | |
GILEAD SCIENCES, INC.
PRODUCT SALES SUMMARY - (Continued)
(unaudited)
| | | | | | | | | | | | | | | | | | | | | | | | | | |
| | Three Months Ended | | Nine Months Ended |
| | September 30, | | September 30, |
| (in millions) | | 2023 | | 2022 | | 2023 | | 2022 |
| Oncology | | | | | | | | |
| Cell Therapy | | | | | | | | |
| Tecartus – U.S. | | $ | 64 | | | $ | 60 | | | $ | 179 | | | $ | 160 | |
| Tecartus – Europe | | 27 | | | 20 | | | 83 | | | 56 | |
| Tecartus – Other International | | 4 | | | 1 | | | 11 | | | 2 | |
| | 96 | | | 81 | | | 272 | | | 217 | |
| | | | | | | | |
| Yescarta – U.S. | | 197 | | | 210 | | | 624 | | | 528 | |
| Yescarta – Europe | | 154 | | | 91 | | | 408 | | | 253 | |
| Yescarta – Other International | | 40 | | | 16 | | | 99 | | | 42 | |
| | 391 | | | 317 | | | 1,130 | | | 823 | |
| | | | | | | | |
| Total Cell Therapy – U.S. | | 261 | | | 270 | | | 802 | | | 688 | |
| Total Cell Therapy – Europe | | 181 | | | 111 | | | 491 | | | 308 | |
| Total Cell Therapy – Other International | | 45 | | | 17 | | | 109 | | | 44 | |
| | 486 | | | 398 | | | 1,402 | | | 1,040 | |
| | | | | | | | |
| Trodelvy | | | | | | | | |
| Trodelvy – U.S. | | 201 | | | 139 | | | 551 | | | 379 | |
| Trodelvy– Europe | | 62 | | | 38 | | | 169 | | | 98 | |
| Trodelvy – Other International | | 21 | | | 3 | | | 44 | | | 8 | |
| | 283 | | | 180 | | | 764 | | | 485 | |
| | | | | | | | |
| Total Oncology – U.S. | | 462 | | | 409 | | | 1,354 | | | 1,067 | |
| Total Oncology – Europe | | 243 | | | 149 | | | 660 | | | 407 | |
| Total Oncology – Other International | | 65 | | | 20 | | | 153 | | | 52 | |
| | 769 | | | 578 | | | 2,167 | | | 1,525 | |
| Liver Disease | | | | | | | | |
| HCV | | | | | | | | |
Ledipasvir / Sofosbuvir(3) – U.S. | | 17 | | | 8 | | | 29 | | | 27 | |
Ledipasvir / Sofosbuvir(3) – Europe | | 2 | | | 5 | | | 11 | | | 13 | |
Ledipasvir / Sofosbuvir(3) – Other International | | 4 | | | 12 | | | 14 | | | 43 | |
| | 23 | | | 25 | | | 54 | | | 83 | |
| | | | | | | | |
Sofosbuvir / Velpatasvir(4) – U.S. | | 215 | | | 241 | | | 643 | | | 629 | |
Sofosbuvir / Velpatasvir(4) – Europe | | 76 | | | 131 | | | 250 | | | 288 | |
Sofosbuvir / Velpatasvir(4) – Other International | | 85 | | | 84 | | | 266 | | | 244 | |
| | 377 | | | 455 | | | 1,159 | | | 1,161 | |
| | | | | | | | |
Other HCV(5) – U.S. | | 28 | | | 34 | | | 80 | | | 88 | |
Other HCV(5) – Europe | | 7 | | | 7 | | | 33 | | | 31 | |
Other HCV(5) – Other International | | 3 | | | 2 | | | 10 | | | 7 | |
| | 38 | | | 44 | | | 123 | | | 127 | |
| | | | | | | | |
| Total HCV – U.S. | | 260 | | | 283 | | | 751 | | | 745 | |
| Total HCV – Europe | | 85 | | | 143 | | | 294 | | | 332 | |
| Total HCV – Other International | | 93 | | | 98 | | | 289 | | | 294 | |
| | $ | 438 | | | $ | 524 | | | $ | 1,335 | | | $ | 1,371 | |
GILEAD SCIENCES, INC.
PRODUCT SALES SUMMARY - (Continued)
(unaudited)
| | | | | | | | | | | | | | | | | | | | | | | | | | |
| | Three Months Ended | | Nine Months Ended |
| | September 30, | | September 30, |
| (in millions) | | 2023 | | 2022 | | 2023 | | 2022 |
| HBV/HDV | | | | | | | | |
| Vemlidy – U.S. | | $ | 112 | | | $ | 129 | | | $ | 295 | | | $ | 306 | |
| Vemlidy – Europe | | 9 | | | 9 | | | 28 | | | 27 | |
| Vemlidy – Other International | | 106 | | | 90 | | | 322 | | | 289 | |
| | 228 | | | 228 | | | 645 | | | 622 | |
| | | | | | | | |
| Viread – U.S. | | 4 | | | 2 | | | 4 | | | 4 | |
| Viread – Europe | | 5 | | | 5 | | | 17 | | | 17 | |
| Viread – Other International | | 12 | | | 15 | | | 40 | | | 48 | |
| | 21 | | | 22 | | | 62 | | | 69 | |
| | | | | | | | |
Other HBV/HDV(6) – U.S. | | — | | | — | | | — | | | 1 | |
Other HBV/HDV(6) – Europe | | 19 | | | 13 | | | 50 | | | 41 | |
| | 20 | | | 14 | | | 51 | | | 42 | |
| | | | | | | | |
| Total HBV/HDV – U.S. | | 116 | | | 131 | | | 299 | | | 311 | |
| Total HBV/HDV – Europe | | 34 | | | 28 | | | 96 | | | 85 | |
| Total HBV/HDV – Other International | | 119 | | | 106 | | | 363 | | | 337 | |
| | 269 | | | 264 | | | 758 | | | 733 | |
| | | | | | | | |
| Total Liver Disease – U.S. | | 376 | | | 413 | | | 1,051 | | | 1,056 | |
| Total Liver Disease – Europe | | 119 | | | 170 | | | 390 | | | 417 | |
| Total Liver Disease – Other International | | 211 | | | 204 | | | 652 | | | 631 | |
| | 706 | | | 788 | | | 2,093 | | | 2,104 | |
| Veklury | | | | | | | | |
| Veklury – U.S. | | 258 | | | 336 | | | 607 | | | 1,179 | |
| Veklury – Europe | | 65 | | | 130 | | | 227 | | | 560 | |
| Veklury – Other International | | 313 | | | 458 | | | 630 | | | 1,166 | |
| | 636 | | | 925 | | | 1,465 | | | 2,905 | |
| Other | | | | | | | | |
| AmBisome – U.S. | | 12 | | | 9 | | | 39 | | | 48 | |
| AmBisome – Europe | | 63 | | | 63 | | | 192 | | | 192 | |
| AmBisome – Other International | | 39 | | | 33 | | | 150 | | | 140 | |
| | 115 | | | 105 | | | 381 | | | 380 | |
| | | | | | | | |
| Letairis – U.S. | | 36 | | | 43 | | | 106 | | | 135 | |
| | | | | | | | |
Other(7) – U.S. | | 34 | | | 28 | | | 91 | | | 91 | |
Other(7) – Europe | | 9 | | | 11 | | | 31 | | | 52 | |
Other(7) – Other International | | 23 | | | 13 | | | 49 | | | 35 | |
| | 65 | | | 52 | | | 171 | | | 178 | |
| | | | | | | | |
| Total Other – U.S. | | 82 | | | 80 | | | 236 | | | 275 | |
| Total Other – Europe | | 72 | | | 75 | | | 224 | | | 244 | |
| Total Other – Other International | | 62 | | | 46 | | | 199 | | | 174 | |
| | 216 | | | 200 | | | 658 | | | 693 | |
| | | | | | | | |
| Total product sales – U.S. | | 4,985 | | | 4,900 | | | 14,196 | | | 13,482 | |
| Total product sales – Europe | | 1,017 | | | 1,064 | | | 3,069 | | | 3,281 | |
| Total product sales – Other International | | 992 | | | 1,013 | | | 2,599 | | | 2,887 | |
| | $ | 6,994 | | | $ | 6,978 | | | $ | 19,864 | | | $ | 19,650 | |
______________________________
(1) Represents Gilead’s revenue from cobicistat (“C”), FTC and TAF in Symtuza (darunavir/C/FTC/TAF), a fixed dose combination product commercialized by Janssen Sciences Ireland Unlimited Company.
(2) Includes Atripla, Emtriva, Sunlenca and Tybost.
(3) Amounts consist of sales of Harvoni and the authorized generic version of Harvoni sold by Gilead’s separate subsidiary, Asegua Therapeutics LLC.
(4) Amounts consist of sales of Epclusa and the authorized generic version of Epclusa sold by Gilead’s separate subsidiary, Asegua Therapeutics LLC.
(5) Includes Vosevi and Sovaldi.
(6) Includes Hepcludex and Hepsera.
(7) Includes Cayston, Jyseleca, Ranexa and Zydelig.
